Potential conflict of interest: Nothing to report.
The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases†
Article first published online: 26 JAN 2008
Copyright © 2008 American Association for the Study of Liver Diseases
Volume 47, Issue 2, pages 762–763, February 2008
How to Cite
Adler, M., Gulbis, B., Moreno, C., Evrard, S., Verset, G., Golstein, P., Frotscher, B., Nagy, N. and Thiry, P. (2008), The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases. Hepatology, 47: 762–763. doi: 10.1002/hep.22085
- Issue published online: 26 JAN 2008
- Article first published online: 26 JAN 2008
To the Editor:
Noninvasive indirect biochemical markers of liver fibrosis have gained popularity, but hepatologists are now facing the difficult dilemma of choosing among the 20 fibrosis markers that are now available.1 Stanislas Pol's group2 claim that FIB-4, initially developed in a human immunodeficiency virus (HIV)-hepatitis C virus (HCV) coinfected population, is a simple, inexpensive, and readily available marker which is reliable for predicting fibrosis in HCV monoinfected patients. It combines platelets, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and age as measurement factors.
However, they did not present comparative area under the receiver operating characteristic curves (AUROCs) with other inexpensive, simple, and readily available scores such as APRI (aspartate aminotransferase-to-platelet ratio index), Forns index, FibroIndex, and FibroTest, which have been widely validated in the HCV3–5 and non-HCV population.6–8 They do not provide data for other liver diseases besides HCV and, finally, they do not give data related to the value of FIB-4 for the prediction of significant (Metavir F2-4 or Brunt S2-4) fibrosis, another important issue for the clinician because this is the cut-off above which progression of fibrosis occurs and medical treatment is needed.
We sought to compare, independently from the promoters, the diagnostic accuracy using AUROCs of the 5 biochemical scores in our HCV population (n = 152) and our global series (n = 290) of patients with chronic liver disease including also hepatitis B virus (n = 16), alcoholic (n = 54), nonalcoholic (n = 38), and other (n = 23) diseases. The prevalence of significant fibrosis (F2-4 or S2-4), advanced fibrosis (F3-4 or S3-4), and cirrhosis (F4 or S4), evaluated histologically using the METAVIR (in the HCV, HBV, and other populations) or the BRUNT classification (in alcoholic and nonalcoholic liver disease) was 77%, 23%, and 12% and 77%, 34%, and 21%, respectively, in the HCV series and the global series. This compares to 36%, 17%, and 7% in Pol's HCV series.
Comparing the performance of the 5 tests in our HCV and global series for the diagnosis of significant fibrosis, advanced fibrosis, and cirrhosis (Table 1), FibroTest and FIB-4 have equal excellent diagnostic power, FibroIndex being the least accurate.
|HCV||All Etiologies||HCV||All Etiologies||HCV||All Etiologies|
In the global series, the Forns index is less accurate than FibroTest and FIB-4 for the diagnosis of cirrhosis and APRI also has less discriminative power than FibroTest and FIB-4 for the diagnosis of significant fibrosis, advanced fibrosis, and cirrhosis.
Thus, the results of our study reinforce the last recommendations9 of the HAS (Haute Autorité de la Santé) in France, which equally ranked the following methods for the diagnosis of liver cirrhosis: liver biopsy, Fibroscan, and FibroTest.
Our data are in accordance with those of Pol's group2 and confirm, in a HCV series where the prevalence of advanced fibrosis is similar, that FIB-4 is an alternative to FibroTest albeit with less expense for 3 clinically pertinent issues: the noninvasive diagnosis of significant fibrosis, advanced fibrosis, and cirrhosis. We also show that FIB-4, which includes simple and common biochemical parameters, is equally valuable and accurate across the 4 most frequent etiologies of chronic liver disease.
- 1Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta 2007; 381: 107–113., , .
- 2FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. HEPATOLOGY 2007; 46: 32–36., , , , , , et al.
- 3Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007; 46: 775–782., , , , , , et al.
- 4FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. HEPATOLOGY 2007; 45: 297–306., , , , , .
- 5A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006; 52: 1887–1896., , , , , , et al.
- 6LIDO Study Group; CYTOL study group. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 6., , , , , , et al.;
- 7Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005; 3: 167–174., , , , , , et al.
- 8Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003; 39: 222–230., , , , , , et al.
- 9Recommandation de Pratique Clinique: Critères diagnostiques et bilan initial de la cirrhose non compliquée. [Practical Clinical Recommendation: Diagnostic criteria and initial assessment of noncomplicated cirrhosis.] Published January 19, 2007. Available at: www.has-sante.fr
Michael Adler*, Béatrice Gulbis, Christophe Moreno*, Sylvie Evrard*, Gontran Verset*, Philippe Golstein*, Brigitte Frotscher, Nathalie Nagy, Philippe Thiry, * Departments of Hepato-Gastroenterology, Hôpital Erasme, Brussels, Belgium, Clinical Biochemistry, Hôpital Erasme, Brussels, Belgium, Pathology, Hôpital Erasme, Brussels, Belgium.